<DOC>
	<DOCNO>NCT01042964</DOCNO>
	<brief_summary>Primary objective : To evaluate safety tolerability , adverse event ( AEs ) , vital sign , ECG , bleed time , evaluation antibody titer safety laboratory test Secondary objective : To evaluate pharmacokinetics pharmacodynamics ( platelet aggregation ) six ascend single intravenous dos PR-15 healthy volunteer</brief_summary>
	<brief_title>Safety , Pharmacokinetic -Dynamic Study PR-15 , Inhibitor Platelet Adhesion</brief_title>
	<detailed_description>Primary objective : To evaluate safety tolerability use adverse event ( AEs ) , vital sign include blood pressure/pulse rate ( BP/PR ) , electrocardiographic examination ( 12 lead ECG ) , bleed time , evaluation antibody titer safety laboratory test ( biochemistry , hematology , coagulation , urinalysis ) Secondary objective : To evaluate pharmacokinetics pharmacodynamics ( collagen-induced platelet aggregation ) six ascend single intravenous dos PR-15 healthy , male volunteer</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Tissue Adhesions</mesh_term>
	<criteria>Healthy , male Caucasians 18 45 year age . Normotensive subject ( systolic BP &lt; 140 mmHg diastolic BP &lt; 90 mmHg ; Body weight 70 90 kg ( BMI 20 25 . Negative result HIV antibody , HBs antigen ( HBsAg ) HCV test ; Signed Informed Consent Form . Normal coagulation function ( aPTT 24 35 second , PT 70 130 % , INR 0.85 1.15 . Subjects take take prescription medication within last 14 day nonprescription medication , especially , antiplatelet drug , within last seven day prior administration trial medication Day 1 . Intake investigational drug within three month prior administration study medication Day 1 . Concomitant use medication include overthecounter preparation . History hypersensitivity , contraindication serious adverse reaction inhibitor platelet aggregation hypersensitivity relate drug ( crossallergy ) excipients study drug . A history clinical evidence cardiac , cardio cerebrovascular , hepatic , renal , pulmonary , endocrine , neurological , infectious , gastrointestinal , haematological , oncological psychiatric disease emotional problem clinically relevant condition , physical finding , ECG laboratory test abnormality , opinion investigator would pose significant risk subject , invalidate Informed Consent limit ability subject comply study requirement interfere otherwise conduct study . Any laboratory value outside normal laboratory reference range Screening randomization , unless approve investigator . Subjects know experienced elevate liver enzyme value also exclude . History alcohol and/or drug abuse ( verify drug screen ) . Blood loss 450 ml last three month Screening . Subjects smoke 5 cigarette per day and/or unable abstain smoking entire inhouse period . Subjects previously enrol trial receive PR15 previous trial . Subjects participate clinical trial last 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>platelet adhesion aggregation</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>stroke</keyword>
	<keyword>inhibition platelet adhesion plaque</keyword>
	<keyword>collagen-induced platelet aggregation</keyword>
</DOC>